) The HIV-Related Malignancies Program represents a group of investigators with a long history of productive and multidisciplinary collaborations. The Program mission is to elucidate the relationship between HIV and co-viral infections and oncogenesis, to improve the management of resulting cancers, and to apply biologic principles to their prevention and ultimate control. Laboratory-based scientists investigate the biology of HIV and related retroviruses, as well as the etiology and pathogenesis of cancers associated with HIV and other viruses such as Human Herpes Virus 8 (HHV-8) and Human Papillomavirus (HPV) in Kaposi's sarcoma (KS) and cervical and anal cancers, respectively. Separate work explores the pathogenesis of HIV-associated non-Hodgkin's lymphomas and the epidemiology of HIV-associated malignancies. Closely coordinated with laboratory and clinical research, epidemiologists explore HPV-related diseases in several cohorts and study the effect of potent antiretroviral regimens on the incidence of cancers. Finally, Program investigators are recognized leaders in clinical trials and conduct numerous studies of novel treatment strategies, frequently linked to affiliated basic investigators. HIV oncology has been a major strength of the University of California San Francisco AIDS effort from the earliest part of the epidemic. As a result, many members have had the opportunity to engage in collaborative work for more than a decade. This work has benefited from the HIV research infrastructure that provides communications, seminars, and core facilities, which are of direct value to the Cancer Center. Examples include a comprehensive investigators' database and large repositories of clinical specimens supported both from the National Cancer Institute and from the Center for AIDS Research (CFAR) grants. Co-leaders of the HIV-Related Malignancies Program are well positioned to make these resources available. Dr. Volberding is the principal investigator of the University of California San Francisco CFAR, and Dr. Kaplan's grants include an AIDS Malignancies Consortium unit and an HIV Malignancy training grant. Furthermore, Program members interact with the other Programs of the Cancer Center and utilize Cancer Center cores. The Cancer Center resources as well as the opportunities for intraprogrammatic collaborations are critical to the continued success of the University of California San Francisco HIV oncology effort.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-03
Application #
6501476
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2001-08-01
Project End
2002-07-31
Budget Start
Budget End
Support Year
3
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794
Olshen, Adam; Wolf, Denise; Jones, Ella F et al. (2018) Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL. J Med Imaging (Bellingham) 5:011014
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160
Brunner, Katja; John, Constance M; Phillips, Nancy J et al. (2018) Novel Campylobacter concisus lipooligosaccharide is a determinant of inflammatory potential and virulence. J Lipid Res 59:1893-1905
Felix, Janine F; Joubert, Bonnie R; Baccarelli, Andrea A et al. (2018) Cohort Profile: Pregnancy And Childhood Epigenetics (PACE) Consortium. Int J Epidemiol 47:22-23u
Cobler, Lara; Zhang, Hui; Suri, Poojan et al. (2018) xCT inhibition sensitizes tumors to ?-radiation via glutathione reduction. Oncotarget 9:32280-32297
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744

Showing the most recent 10 out of 192 publications